Interestingly, in the current study, treatment of OVX+T2D rats with the GPER agonist G-1 resulted in an improvement in both systolic and diastolic function of the heart, as measured by an increase in LVSP, ± dp/dt max, and reduction in LVEDP. Here, GPER1 is linked to type 2 diabetes mellitus.